MD HB996

Retailers must disclose on product labels the factual basis for any claims made about phenibut products, and may not sell phenibut products that lack FDA recognition as a dietary ingredient or approved drug

Sales of phenibut products to individuals under age 21 are prohibited, and products must list the amount of beta-phenyl-gamma-aminobutyric acid HCl on packaging

Advertising therapeutic benefits of phenibut is banned, along with marketing to minors using cartoons, superheroes, video game references, or images of individuals appearing under age 27

Civil penalties range from $1,000 for first labeling violations to $2,000 for subsequent violations; selling non-compliant, adulterated, or contaminated products or to underage buyers is a misdemeanor punishable by up to $5,000 fine and/or 90 days imprisonment

The Maryland Department of Health must adopt regulations to implement the law, which takes effect October 1, 2025